University of Economics, Prague
Faculty of Finance and Accounting Study programme “Finance and Accounting”
Page 1/2
M a s t e r T h e s i s E v a l u a t i o n Supervisor form
Student name: Ekaterina Matveeva
Title of the thesis: Strategic and Financial Analysis of Pfizer Company
Year of the defence: 2021 Supervisor name
and affiliation:
Ing. Barbora Rydlova, Ph.D., Department of corporate finance and business valuation
Reviewer name and affiliation:
Ing. Barbora Nohynkova, Department of corporate finance and business valuation
THESIS CONTENT SUMMARY:
The thesis is focused on financial and strategic analysis of Pfizer company with the aim to outline the prospective development of Pfizer´s market share in the following years. The analysis is performed based on a very broad information and market data that the author has managed to gather from a substantial number of sources. Within the market analysis the author used regression analysis to identify the drivers of the market and use it for forecast. The competitive and financial analysis is based on comparison with the closest competitors Novartis, Merck and Sanofi. The comparison is multicriterial and systematic, it has clear conclusions, well supported by arguments.
OBJECTIONS AND REMARKS:
The strength of the thesis:
- The volume of the information included - Detail analysis of many factors
- The subject is not easy - to analyse a global company operating in many segments and in the same time in many geographical locations
- A well done summary in the way of SWOT analysis The weaknesses of the thesis:
- More consulting time needed with the supervisor
Page 2/2 QUESTIONS FOR THE DEFENCE:
1. Do you expect Covid-19 to have a positive or negative influence on the company´s financial figures in the short and long run? Please, explain.
2. Name the key drivers that you identified that are going to cause the market share of Pfizer to grow in the future after the decline in the recent years.
